Document Detail

Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis.
Jump to Full Text
MedLine Citation:
PMID:  22466613     Owner:  NLM     Status:  MEDLINE    
Variants associated with meconium ileus in cystic fibrosis were identified in 3,763 affected individuals by genome-wide association study (GWAS). Five SNPs at two loci near SLC6A14 at Xq23-24 (minimum P = 1.28 × 10(-12) at rs3788766) and SLC26A9 at 1q32.1 (minimum P = 9.88 × 10(-9) at rs4077468) accounted for ~5% of phenotypic variability and were replicated in an independent sample of affected individuals (n = 2,372; P = 0.001 and 0.0001, respectively). By incorporating the knowledge that disease-causing mutations in CFTR alter electrolyte and fluid flux across surface epithelium into a hypothesis-driven GWAS (GWAS-HD), we identified associations with the same SNPs in SLC6A14 and SLC26A9 and established evidence for the involvement of SNPs in a third solute carrier gene, SLC9A3. In addition, GWAS-HD provided evidence of association between meconium ileus and multiple genes encoding constituents of the apical plasma membrane where CFTR resides (P = 0.0002; testing of 155 apical membrane genes jointly and in replication, P = 0.022). These findings suggest that modulating activities of apical membrane constituents could complement current therapeutic paradigms for cystic fibrosis.
Lei Sun; Johanna M Rommens; Harriet Corvol; Weili Li; Xin Li; Theodore A Chiang; Fan Lin; Ruslan Dorfman; Pierre-François Busson; Rashmi V Parekh; Diana Zelenika; Scott M Blackman; Mary Corey; Vishal K Doshi; Lindsay Henderson; Kathleen M Naughton; Wanda K O'Neal; Rhonda G Pace; Jaclyn R Stonebraker; Sally D Wood; Fred A Wright; Julian Zielenski; Annick Clement; Mitchell L Drumm; Pierre-Yves Boëlle; Garry R Cutting; Michael R Knowles; Peter R Durie; Lisa J Strug
Related Documents :
22851933 - Blood group abo genotyping in paternity testing.
22403733 - A highly sensitive quantitative real-time pcr assay for determination of mutant jak2 ex...
19195803 - Genetic variant of glutathione peroxidase 1 in autism.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Nature genetics     Volume:  44     ISSN:  1546-1718     ISO Abbreviation:  Nat. Genet.     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-06-07     Completed Date:  2012-07-02     Revised Date:  2014-09-19    
Medline Journal Info:
Nlm Unique ID:  9216904     Medline TA:  Nat Genet     Country:  United States    
Other Details:
Languages:  eng     Pagination:  562-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Amino Acid Transport Systems, Neutral / genetics
Antiporters / genetics
Cell Membrane / metabolism*
Cystic Fibrosis / genetics*
Cystic Fibrosis Transmembrane Conductance Regulator / genetics*
Genetic Predisposition to Disease*
Genome-Wide Association Study
Ileus / genetics*
Intestinal Obstruction / etiology
Polymorphism, Single Nucleotide / genetics*
Sodium-Hydrogen Antiporter / genetics
Grant Support
HG-0004314/HG/NHGRI NIH HHS; K23 DK083551/DK/NIDDK NIH HHS; K23 DK083551/DK/NIDDK NIH HHS; K23 DK083551-04/DK/NIDDK NIH HHS; MOP 258916//Canadian Institutes of Health Research; MOP 84287//Canadian Institutes of Health Research; P30 DK027651/DK/NIDDK NIH HHS; P30 DK027651-26S1/DK/NIDDK NIH HHS; R01 DK066368/DK/NIDDK NIH HHS; R01 DK066368/DK/NIDDK NIH HHS; R01 DK066368-05/DK/NIDDK NIH HHS; R01 HL068890/HL/NHLBI NIH HHS; R01 HL068890/HL/NHLBI NIH HHS; R01 HL068890-10/HL/NHLBI NIH HHS; R01 HL068927/HL/NHLBI NIH HHS; R01 HL068927-10/HL/NHLBI NIH HHS; R01 HL095396/HL/NHLBI NIH HHS; R01 HL095396/HL/NHLBI NIH HHS; R01 HL095396-04/HL/NHLBI NIH HHS; R01 HL68927/HL/NHLBI NIH HHS; R03 HG004314-02/HG/NHGRI NIH HHS
Reg. No./Substance:
0/Amino Acid Transport Systems, Neutral; 0/Antiporters; 0/CFTR protein, human; 0/SLC26A9 protein, human; 0/SLC6A14 protein, human; 0/Sodium-Hydrogen Antiporter; 0/sodium-hydrogen exchanger 3; 126880-72-6/Cystic Fibrosis Transmembrane Conductance Regulator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-journal-id): 9216904
Journal ID (pubmed-jr-id): 2419
Journal ID (nlm-ta): Nat Genet
Journal ID (iso-abbrev): Nat. Genet.
ISSN: 1061-4036
ISSN: 1546-1718
Article Information
Download PDF

nihms-submitted publication date: Day: 2 Month: 3 Year: 2012
Print publication date: Year: 2012
pmc-release publication date: Day: 01 Month: 7 Year: 2012
Volume: 44 Issue: 5
First Page: 562 Last Page: 569
ID: 3371103
PubMed Id: 22466613
DOI: 10.1038/ng.2221
ID: nihpa359534

Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis
Lei Sun12*
Johanna M Rommens34*
Harriet Corvol56
Weili Li17
Xin Li7
Theodore Chiang7
Fan Lin3
Ruslan Dorfman3
Pierre-François Busson8
Rashmi V Parekh3
Diana Zelenika9
Scott Blackman10
Mary Corey7
Vishal Doshi11
Lindsay Henderson11
Kathleen Naughton11
Wanda K O'Neal12
Rhonda G Pace12
Jaclyn R Stonebraker12
Sally D Wood12
Fred A Wright13
Julian Zielenski3
Annick Clement56
Mitchell L Drumm14
Pierre-Yves Boëlle68
Garry R Cutting1011
Michael R Knowles12
Peter R Durie1516
Lisa J Strug71
1Biostatistics Division, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada
2Department of Statistics, University of Toronto, Toronto, Ontario, Canada
3Program in Genetics and Genome Biology, the Hospital for Sick Children, Toronto, Ontario, Canada
4Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada
5AP-HP, Hospital Trousseau, Pediatric Pulmonary Department, Inserm U938, Paris, France
6Pierre et Marie Curie University-Paris 6, Paris, France
7Program in Child Health Evaluative Sciences, the Hospital for Sick Children, Toronto, Ontario, Canada
8AP-HP, St Antoine Hospital, Biostatistics Department, Inserm UMR-S707, Paris, France
9Centre National de Génotypage, CEA, Evry, France
10Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
11McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
12Cystic Fibrosis-Pulmonary Research and Treatment Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
13Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
14Departments of Pediatrics and Genetics, Case Western Reserve University, Cleveland, Ohio, USA
15Program in Physiology and Experimental Medicine, the Hospital for Sick Children, Toronto, Ontario, Canada
16Department of Pediatrics, University of Toronto, Toronto, Ontario, Canada
Correspondence: Correspondence should be addressed to Lisa Strug:
*These authors contributed equally to this work

Cystic fibrosis is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene1. CFTR is a chloride channel located on the apical membrane of epithelia, where ion conduction and solute trafficking contribute to the regulation of transepithelial fluid flow. Individuals with the same loss-of-function CFTR mutations have variable disease severity, and differentially affected CF-associated organs including lung, pancreas, liver, intestines, and vas deferens; thus additional features, including other genes (referred to as modifier genes) may affect disease pathophysiology. Approximately 15% of CF patients have severe intestinal obstruction at birth, a complication known as meconium ileus2. Meconium ileus develops in utero, and presents following birth with complete intestinal obstruction that requires either medical or surgical intervention. This neonatal complication is highly indicative of CF, occurs in either sex, displays notable heritability exceeding 88%3, and is likely minimally affected by environmental influences.

The North American CF Gene Modifier Consortium has accumulated 3,763 participants with ‘severe’ (pancreatic exocrine insufficient) CFTR alleles and genome-wide genotype data at 543,927 SNP loci4,5 (Table 1 and Online Methods). The definition of meconium ileus was consistent within the consortium and was recorded following rigorous chart review. A conventional GWAS for meconium ileus used a generalized estimating equations (GEE) model6 to include collected sibling-pairs, and led to five genome-wide significant SNPs (P<5×10−8)7 from two regions that include SLC26A9 on chromosome 1 and SLC6A14 on chromosome X (Fig. 1, Supplementary Fig. 1, Table 2; sex-specific results in Supplementary Table 1). CFTR was not a significant confounder or effect modifier when incorporated in the GWAS (Supplementary Fig. 2 and Supplementary Table 2), indicating SLC6A14 and SLC26A9 are independent contributors to meconium ileus. We then replicated the associations in SLC6A14 (min P=0.001) and SLC26A9 (min P=0.0001) with meconium ileus in an independent combined collection from North America and France (Table 2).

The signal intensity plots of the associated SNPs reflected autosomal- and X-associated SNPs at SLC26A9 and SLC6A14, respectively. Imputation analysis using MACH and minimac8,9 identified the same regions of association as the genotyped SNPs (Online Methods, Supplementary Fig. 3). The five associated SNPs in SLC6A14 and two in SLC26A9 (Fig. 1b and 1c) are positioned just upstream of their respective transcription start sites such that binding of activating or repressing transcription factors may be affected as highlighted by ENCODE data10 (data not shown). Neither SLC6A14 nor SLC26A9 coding regions exhibit evidence for CNVs; however, there is a gap in the reference sequence >10 kb upstream of the SLC26A9 locus.

The seven SNPs genotyped (Table 2) in the two genes account for <5% of the meconium ileus variation, estimated by pseudo R-squared11, likely reflecting the common problems in association studies of locus heterogeneity and low power given the available sample size. Whereas conventional GWAS is often considered for complex disease mapping, modifier gene studies could incorporate disease etiology and pathobiology information to increase power and account for heterogeneity. To do so, we proposed application of GWAS with consideration of a hypothesis (and so is hypothesis-driven; GWAS-HD) to systematically prioritize SNPs for genome-wide analysis. The highest priority markers are also evaluated as a set to test the statistical significance of the hypothesis used for prioritization (Supplementary Fig. 4).

The GWAS-HD prioritization in this CF application is based on the knowledge that a major source of CF pathophysiology is impaired fluid and electrolyte flux in epithelia of CF-affected organs. The polarized epithelial layer forms a highly selective barrier between organ and ductal interfaces. Transepithelial ‘function’ is achieved by cell polarization whereby many determinants and regulators of fluid, solute and ion transport reside at the apical membrane alongside CFTR, with contributing features from basolateral surfaces. We have shown in a mouse model that CFTR function in the gastrointestinal epithelium is critical for preventing intestinal obstructions12. Thus, we hypothesized that with loss of CFTR, (genetic) variation in other apical membrane constituents could modify CF phenotypes, such as meconium ileus.

A list of 157 gene products (Fig. 2 and Supplementary Table 3) was annotated as localized to the apical plasma membrane using AmiGO13 with Gene Ontology data14,15. CFTR and many solute transporters were included. However, the brush border membrane protein SLC6A14 was not listed, reflecting the high specialization of its corresponding intestinal cavity and a limitation of the GO annotation that we accepted without additional curation to avoid bias. In total, 3,814 GWAS SNPs were within ±10 kb of the boundaries of 155 genes (NCBI36/hg18); 2 genes were not tagged by any of the GWAS SNPs.

To implement the GWAS-HD for meconium ileus using the apical hypothesis, we first prioritized the genome-wide markers by assigning the 3,814 SNPs of the apical genes to a high priority group and all remaining genome-wide SNPs to a low priority group. We then performed two statistical analyses (Supplementary Fig. 4 and Online Methods). The first, analogous to a conventional GWAS, was to conduct single-SNP association analysis using all of the 543,927 GWAS SNPs at the genome-wide level, however after up-weighting the 3,814 apical SNPs via the SFDR control.16 The second analysis, focusing only on the 3,814 high priority SNPs using a multi-SNP/gene analysis, tested the prioritization hypothesis itself to determine if multiple proteins present on the apical plasma membrane contribute to meconium ileus susceptibility.

As in the conventional GWAS, SNPs from SLC6A14 showed the strongest evidence for association with meconium ileus in the single-SNP GWAS-HD analysis (Supplementary Fig. 5), despite not being in the high priority group, reflecting the robustness of SFDR17. In addition, SNPs from SLC26A9, and two additional apical genes, ATP2B2 and SLC9A3, showed association evidence with q values <0.05 (Table 3). A gene-based analysis (Online Methods) of ATP2B2 (P=0.0006) and SLC9A3 (P=0.0001) indicated evidence for allelic heterogeneity after comparing results with single-SNP analysis (Table 3). SLC9A3 was replicated in the French cohort (P=0.017) while ATP2B2 was not (P=0.283) (Supplementary Table 3).

Next, restricting analysis to the 3,814 SNPs annotated to the 155 apical genes (which does not include SLC6A14), we tested the apical prioritization hypothesis as part of the GWAS-HD. Here we observed genome-wide significant evidence for association between meconium ileus and multiple constituents of the apical plasma membrane (permutation P=0.0002, testing all 3,814 SNPs jointly and not subject to multiple hypothesis testing (Fig. 2a and 2b)). Even with the exclusion of SLC26A9 (as well as SLC6A14), the apical hypothesis remained significant (P=0.0058). Thus, GWAS-HD further established the involvement of other genes coding for apical constituents despite insufficient power to detect individual SNPs, even within the context of our prioritized GWAS. For comparison, we also constructed a null hypothesis list of membrane-localized genes. As expected, the 224 GO-annotated nuclear envelope genes tagged by 3,537 GWAS SNPs showed no relationship with meconium ileus (permutation P=0.4639; Fig. 3).

The French cohort with genome-wide data provided independent validation of the apical hypothesis (permutation P=0.022; Fig. 2c and 2d; Online Methods). The statistical significance of this gene set (which excludes SLC6A14) in the French cohort remained after further excluding SLC26A9 (P=0.021) and then both SLC26A9 and SLC9A3 (P=0.023). Although analysis of the apical hypothesis in a larger independent cohort should be considered as part of future efforts, the replication in the smaller French cohort supports a (common) mechanism of contributing genes, even though the responsible gene variants across the two datasets may not be the same.

To determine which apical genes were driving the association, the degree of genetic heterogeneity in meconium ileus, and the common contributors across the French and North American samples, we implemented Lasso18. Using the North American sample, we jointly analyzed all 3,740 SNPs available in the apical genes (which include SLC26A9 and SLC9A3), and SLC6A14 (Online Methods), that were not in perfect linkage disequilibrium. Forty-eight SNPs spanning 36 different genes were retained by Lasso in the multivariate regression model (Supplementary Table 3). These SNPs jointly explained ~17% of the meconium ileus variation in the North American sample. The percentage explained by the same 48 SNPs in the French sample was 8.1% (Online Methods), presumably due to the smaller sample size and genetic heterogeneity. We then tested the significance of a score for each individual in the French cohort constructed from a weighted sum of the number of risk alleles (defined in the North American sample) across the 48 SNPs19. The significant association between meconium ileus and this score (P=0.0137; Online Methods) provided additional complimentary evidence of common contributors between the two cohorts, with SNPs in SLC9A3 and SLC6A14 being two specific examples.

In summary, conventional GWAS identified SNPs in SLC6A14 and SLC26A9 as significantly associated with meconium ileus. GWAS-HD single-SNP analysis identified the same SNPs in SLC6A14 and SLC26A9, as well as SNPs in SLC9A3; and multi-SNP analysis provided evidence that multiple constituents of the apical plasma membrane are collectively associated with meconium ileus, yielding considerable additional information beyond single SNP/gene associations. GWAS-HD can be applied to other Mendelian disorders, or even complex traits provided there is a biologically-based hypothesis and participating relevant genes can be compiled.

Although gene prioritization has been used in other approaches such as pathway or gene enrichment analyses2022, GWAS-HD involves key differences. First, in contrast to the previous inclusion/exclusion approaches where all genotyped SNPs/genes are not analyzed simultaneously, GWAS-HD performs parallel single-SNP analysis of all GWAS SNPs, and multi-SNP/gene analysis focusing on the set of SNPs/genes of interest. The prioritized single-SNP analysis interrogates all available SNPs via the SFDR control, yet enables increased statistical power for regions favoured a priori. For example, SLC6A14 would be omitted by inclusion/exclusion approaches, yet it remained the highest ranked gene for association with meconium ileus in GWAS-HD. Second, methods such as interactive pathway analysis can be restrictive because contributing genes/proteins must relate to each other via direct or indirect links, which may be disturbed when a cog component (such as CFTR) is dysfunctional in the disease state. While gene products that participate in maturation or delivery of CFTR may be contributory, consideration of local components of processes that may compensate for the ion and fluid flow disturbance in CF is enabled in the apical hypothesis. Third, distinct from an exhaustive search of all plausible interactive pathways, GWAS-HD focuses on a single biological hypothesis and provides statistical significance for all genes involved jointly, alleviating the multiple testing burden.

It should be noted that the specific statistics or models used in our GWAS-HD application such as SFDR, Lasso, and the sum and score statistics may not be the most powerful ones in any specific setting. For example, the adaptive rank truncated product statistic23 could be used to identify the common subset of associated apical genes across two samples; and there are alternative weighting and prioritization approaches24.

The SLC9A3 gene codes for a sodium/hydrogen exchanger that when disrupted has been shown to decrease intestinal obstructions in a CF mouse model25. SLC6A14 codes for a sodium- and chloride-dependant neutral and basic amino acid transporter26,27. SLC26A9 encodes an anion transporter, likely a chloride channel with multiple modes that include chloride/bicarbonate exchanger and sodium-anion cotransporter capabilities28. It has also been reported to physically interact with CFTR29 and be influenced by CFTR activity, at least in lung-related tissues30.

It is notable that SLC9A3 has previously been associated with infections and pulmonary function in CF31. In the consortium discovery sample, rs6864158 (MAF=0.43) in SLC9A3 was associated with both the lung (P=0.0003, analyzed previously5) and meconium ileus (P=0.0001); this provides evidence that some genes may play a role in multiple CF co-morbidities. Both SLC6A14 and SLC26A9 are robustly expressed in human lung epithelia, sweat gland, as well as intestinal epithelia as measured by RT-PCR (not shown). We anticipate that meconium ileus modifier genes may also influence early pathology in other CF-affected organs, and thus could provide important insights into the mechanisms of CF disease severity and co-morbidities.

These findings collectively have important practical implications for CF, where therapeutic strategies should consider pharmacologic modulation of epithelial function, in complementation with paradigms aimed at directly improving function or delivery of the mutated CFTR gene product to the apical membrane32.










  • GWAS-HD Design and Concept
  • GWAS Design
  • Manuscript Preparation
  • Statistical Analysis
  • Data Coordination
    FAW, LH, SB, VD
  • Recruitment and Phenotyping
  • Genotyping
  • Bioinformatics


The authors declare no competing financial interests.


The authors would like to thank the patients and families who participated in this study, the CFF Patient Registry, the University of North Carolina DNA Laboratory, and Genome Quebec and McGill University Innovation Centre; Isidro Wong for technical help with the replication genotyping; the computer specialists and the clinical research assistants, Jean-François Vibert, Malika Mahloul, Delphine Michon, Alexandra Blondel and Pauline Touche involved in the study design and patients’ recruitment of the French sample; Evan Hawbaker and Anthony Dang for data coordination; Drs. Yves Berthiaume, Andrew Sandford and Peter Pare for ascertainment of Canadian phenotype data and DNA; Jennifer Breaton, Mary Christofi, Nicole Anderson, Katherine Keenan, Chelsea Taylor and Julie Avolio for coordinating and verifying the Canadian data collection; Edgar Crowdy for database development and management in Canada; Sarah Norris, Adriane Kohl, Patricia Miller, Leia Charnin, Will Hannah, and Sonya Adams for recruitment, phenotyping and data entry at the University of North Carolina; Whitney Wolf for DNA, and Hemant Kelkar, Thomas Randall and Annie Xu for bioinformatics at the University of North Carolina; Nulang Wang, Kyle Kaniecki, Jenna Bonner and Christopher Watson for technical assistance at Johns Hopkins University.

This work was supported in part by Genome Canada through the Ontario Genomics Institute as per research agreement 2004-OGI-3-05 with the Ontario Research Fund, Research Excellence Program; the University of Toronto McLaughlin Centre; the Ontario Ministry of Research and Innovation Early Researcher (LJS); Cystic Fibrosis Canada (CFC) grants to PD, JZ, and LJS; Natural Sciences and Engineering Research Council (NSERC) to LJS; NSERC (250053-2008) and Canadian Institutes of Health Research (CIHR;MOP 84287) grants to LS; Lloyd Carr-Harris Foundation; the US National Institutes of Health grants: R01HL68927, K23DK083551, R01HL068890, R01DK066368, R01HL095396, P30DK027651, HG-0004314; U.S. Cystic Fibrosis Foundation (CFF) grants: CUTTIN06P0, R025-CR07, KNOWLE00A0, RDP-R026-CR07, DRUMM0A00; Flight Attendant Medical Research Institute grant: FAMRI2006; Lawson Wilkins Pediatric Endocrine Society grant: LWPES Clinical Scholar Award; Institut National de la Santé et de la Recherche Médicale, Assistance Publique-Hôpitaux de Paris, Université Pierre et Marie Curie Paris, Agence Nationale de la Recherche (R09186DS), Direction Générale de la Santé, Association Vaincre La Mucoviscidose, Chancellerie des Universités (Legs Poix), Association Agir Informer Contre la Mucoviscidose, GIS-Institut des Maladies Rares. Funds for genome-wide genotyping of North American participants were generously provided by the U.S. CFF. RD received a Joint Fellowship from the CIHR and Ontario Women's Health Council.

Contributing North American CF Centers and Principal Investigators

Aaron,S., Ottawa General Hospital, Ottawa, Canada/Accurso,F., University of Colorado Health Sciences Center, CO/Acton,J., Cincinnati Children's Hospital and Medical Center, OH/Ahrens,R., University of Iowa Hospitals & Clinics, IA/Aljadeff,G., Lutheran General Children's Hospital, IL/Allard,C., Hôpital de Chicoutimi, Chicoutimi, Canada/Amaro,R., University of Texas at Tyler Health Center, TX/Anbar,R., SUNY Upstate Medical University, NY/Anderson,P., University of Arkansas, AR/Atlas,A., Morristown Memorial Hospital, NJ/Bell,S., The Prince Charles Hospital, Australia/Berdella,M., St. Vincents Hospital & Medical Center, NY /Berthiaume,Y., Hôtel-Dieu De Montréal/Biller,J., Children's Hospital of Wisconsin, WI/Bishop,G., Saint John Regional Hospital, Saint John, Canada/Bjornson,C., Alberta Children’s Hospital, Calgary, Canada/Black,H., Asthma & Allergy Specialists, Charlotte, NC/Black,P., Children's Mercy Hospital, MO/Boas,S., Children's Asthma Respiratory&Exercise Specialists, IL/Boland,M., Children’s Hospital of Eastern Ontario, Ottawa, Canada/Borowitz,D., Women & Children's Hospital of Buffalo, NY/Boswell,R., University of Tennessee, TN/Boucher,J., Centre Hospitalier Régional de Rimouski, Rimouski, Canada/Bourke,B., Our Lady’s Children Hospital, Ireland/Bowman,C.M., Medical University of South Carolina, SC/Boyle,M., Johns Hopkins Hospital, MD/Brown,C., California Pacific Medical Center, CA/Brown,D., Pediatric Pulmonary Associates., SC/Brown,N., University of Alberta Hospitals, Edmonton, Canada/Brusky,J., University Hospital, Saskatoon, Canada/Caffey,L.F., University of New Mexico, NM/Cantin,A., Centre hospitalier universitaire de Sherbrooke, Fleurimont, Sherbrooke, Canada/Casciaro,R., Istituto G. Gaslini, Italy/Castellani,C., Azienda Ospedaliera de Verona, Italy/Chatfield,B., University of Utah Health Sciences Center, UT/Chesrown,S., University of Florida, FL/Chilvers,M., B.C. Children’s Hospital, Vancouver, Canada/Chipps,B., Sutter Medical Center, CA/Cipolli,M., Azienda Ospedaliera de Verona, Italy/Clancy,J.P., University of Alabama at Birmingham, AL/Cohen,R., Kaiser Permanente, OR/Colombo,J., University of Nebraska Medical Center, NE/Cronin,J., Women & Children's Hospital of Buffalo, NY/Cruz,M., St. Mary's Medical Center, FL/Cunningham,J., Cook Children's Medical Center, TX/Davidson,G., B.C. Children’s Hospital, Vancouver, Canada/Davies,J, University of New Mexico, NM/Davies,L., University of New Mexico, SOM, NM/Debray,D., Centre Hospitalier Universitaire de Bicêtre, France/DeCelie-Germana,J., Schneider Children's Hospital, NY/Devenny,A., Royal Hospital for Sick Children, Scotland/DiMango,E., Columbia University Medical Center, NY/Doornbos,D., Via-Christi, St. Francis Campus, KS/Dozor,A., New York Medical College-Westchester Medical Center, NY/Dunitz,J., University of Minnesota, MN/Egan,M., Yale University SOM, CT/Eichner,J., Great Falls Clinic, MT/Elliot,G., Virginia Commonwealth University, Virginia/Farrell,J., Janeway Child Health Centre, St. John’s, Canada/Ferkol,T., St. Louis Children's Hospital, MO/Fiel,S., Morristown Memorial Hospital, NJ/Flume,P., Medical University of South Carolina, SC/ Freitag,A.,Chedoke-McMaster Hospital, Hamilton, Canada/ Franco,M., Miami Children's Hospital, FL/Froh,D., University of Virginia Health System, VA/Garey,N., Saint John Regional Hospital, Saint John, Canada/Geller,D., Nemours Children's Clinic Orlando, FL/Gershan,W., Children's Hospital of Wisconsin, WI/Gibson,R., Children’s Hospital & Regional Medical Center, WA/Giusti,R., Long Island College Hospital, NY/Gjevre,J., University Hospital, Saskatoon, Canada/Gondor,M., University of South Florida, FL/Gong,G., Phoenix Children's Hospital, AZ/Goulet,S., Centre Hospitalier Régional de Rimouski, Rimouski, Canada/Guill,M., Medical College of Georgia, GA/Gutierrez,H., University of Alabama at Birmingham, AL/Hadeh,A., Drexel University College of Medicine, PA/Hardy,K., Children's Hospital - Oakland, CA/Henderson,K., Janeway Child Health Centre, St. John’s, Canada/Hiatt,P., Texas Children's Hospital, TX/Hicks,D., Children's Hospital of Orange County, CA/Holmes,B., Regina General Hospital, Regina, Canada/Holsclaw,D., University of Pennsylvania, PA/Holzwarth,P., St. Vincent Hospital - Genetics, WI/Honicky,R., Michigan State University, MI/Howenstine,M., Riley Hospital for Children, IN/Hughes,D., IWK Health Centre, Halifax, Canada/Jackson,M., St. Mary’s Hospital, Kitchener, Canada/James,P., Lutheran Hospital, IN/ Jenneret A., Hôtel Dieu de Montréal, Montréal, Canada/Joseph,P., University of Cincinnati, OH/Kanga,J., University of Kentucky, KY/Katz,M., Baylor College of Medicine, TX/Kent,S., Victoria General Hospital, Victoria, Canada/Kepron,W., Health Sciences Centre, Winnipeg, Canada/Knowles,M., University of North Carolina at Chapel Hill, NC/Konig,P., University of Missouri-Columbia, MO/Konstan,M., Case Western Reserve University, OH/ Kovesi,T., Children’s Hospital of Eastern Ontario, Ottawa, Canada/Kramer,J., Oklahoma Cystic Fibrosis Center, OK/Kraynack,N., Children's Hospital Medical Center of Akron, OH/Kumar,V., Laurentian Hospital, Sudbury, Canada/Lacaille,F., Hôpital Necker-Enfants Malades, France/Lahiri,T., Fletcher Allen Health Care, VT/Landon,C., Pediatric Diagnostic Center, CA/Lands,L., Montréal Children’s Hospital, Montréal, Canada/Lapin,C., Connecticut Children's Medical Center, CT/Larj,M., Wake Forest University Baptist Med. Ctr., NC/Lavoie,A., Hôtel-Dieu De Montréal/Ledbetter,J., TC Thompson Children's Hospital, TN/Lee,R., Naval Medical Center - Portsmouth, VA/Leigh,M., University of North Carolina at Chapel Hill, NC/Lester,L., University of Chicago Children's Hospital, IL/Lever,T., Eastern Maine Medical Center, ME/Levy,H., Children's Hospital Boston, MA/Lieberthal,A., Kaiser Permanente Southern California, CA/Liou,T., University of Utah, UT/Lipton,A., National Naval Medical Center, MD/Lobritto,S., Columbia University Medical Center, New York/Lothian,B., Royal University Hospital, Saskatoon, Canada/Lougheed,D., Hotel Dieu Hospital, Kingston, Canada/Lyttle,B., London Health Sciences Centre, London, Canada/Macek,M., Charles University and University Hospital Motol, Czech Republic/Malhotra,K., Grand River Hospital, Kitchener, Canada/Marcotte,J., Hôpital Sainte-Justine, Montréal, Canada/Matouk,E., Montréal Chest Institute, Montréal, Canada/McCarthy,M., Providence Medical Center, WA/McColley,S., Children's Memorial Hospital & Northwestern University, IL/McCoy,K., Columbus Children's Hospital, OH/McNamara,J., Children's Hospitals and Clinics of Minneapolis, MN/Mencin,A., Columbia University Medical Center, New York/Michael,R., Queen Elizabeth II Health Sciences Centre, Halifax, Canada/Miller,S., University of Mississippi Medical Center, MS/Milot,M., Hôpital de Chicoutimi, Chicoutimi, Canada/Moffett,K., West Virginia University, WV/Montgomery,M., Alberta Children’s Hospital, Calgary, Canada/Moore,P., Vanderbilt University Medical Center, TN/Morgan,W., Tucson Cystic Fibrosis Center, AZ/Morris,R., Janeway Children’s Health & Rehabilitation, St. John’s, Canada/Morse,M., Methodist Children's Hospital, TX/Moskowitz,S., Children’s Hospital & Regional Medical Center, WA/Moss,R., Stanford University Medical Center, CA/Murphy,P., University of Nebraska Medical Center, NE/Nakielna,E., St. Paul’s Hospital, Vancouver, Canada/Nasr,S., University of Michigan Medical Center, MI/Nassri,L., Sparks Regional Medical Center, AR/Naureckas,E., University of Chicago Hospitals, IL/Nielson,D., University of California at San Francisco, CA/Noseworthy,M., Janeway Children’s Health & Rehabilitation, St. John’s, Canada/Noyes,B., St. Louis University, MO/Olivier,K., Wilford Hall USAF Med. Ctr. San Antonio, TX/Olson,E., University of Florida, FL/Omlor,G., Akron Children's Hospital, OH/Orenstein,D., Children's Hospital of Pittsburgh, PA/O'Sullivan,B., University of Massachusetts Memorial Health Care, MA/Parker,H.W., Dartmouth-Hitchcock Medical Center, NH/Passero,M., Brown University Medical School Rhode Island Hospital, RI/Pasterkamp,H., Children’s Hospital of Winnipeg, Winnipeg, Canada/Paterson,N., London Health Sciences Centre, London, Canada/Pedder,L., Chedoke-McMaster Hospital, Hamilton, Canada/Perkett,E., Vanderbilt University Medical Center, TN/Perrault,L., Centre de santé et des services sociaux de Rouyn-Noranda, Quebec, Canada/Perry,G., University of Kansas Medical Center, KS/Petit,N., Center Hospitalier Rouyn-Noranda, Rouyn-Noranda, Canada/Pian,M., University of California San Diego Children's Hospital, CA/Pineau,L., Grand River Hospital, Kitchener,Canada/Platzker,A., Children's Hospital of Los Angeles, CA/Popa,C., Centre de santé et des services sociaux de Rouyn-Noranda, Quebec, Canada/Prestidge,C., Children's Medical Center of Dallas, TX/Price,A., London Health Sciences Centre, London, Canada/Rabin,H., Foothills Medical Centre, Calgary, Canada/Radford,P., Phoenix Children's Hospital, AZ/Ratjen,F., The Hospital for Sick Children, Toronto, Canada/Regelmann,W., University of Minnesota, MN/Ren,C., University of Rochester Medical Center, Strong Memorial Hospital, NY/Repetto,G., Universidad del Desarrollo de Santiago, Chile/Retsch-Bogart,G., University of North Carolina at Chapel Hill, NC/Richards,W., Memphis Lung Physicians, MS/Riva,M., Via-Christi, St. Francis Campus, KS/Rivard,L., Centre hospitalier universitaire de Sherbrooke, Fleurimont, Sherbrook, Canada/Roberts,D., Providence Medical Center, AK/Rock,M., University of Wisconsin Hospital, WI/Rosen,J., Albany Medical College, NY/Rowland,M., Our Lady’s Children’s Hospital, Ireland/Royall,J., Childrens Hospital of Oklahoma, OK/Rubenstein,R., Children's Hospital of Philadelphia, PA/Ruiz,F., University of Mississippi Med. Ctr., MS/Scanlin,T., Children's Hospital of Philadelphia, PA/Schechter,M., Emory University School of Medicine, GA/Schmidt,H.J., Virginia Commonwealth University, VA/Schwartzman,M., Joe DiMaggio Children's Hospital, FL/Scott,P., Georgia Pediatric Pulmonology Assoc., PC, GA/Shay,G., Kaiser Permanente Medical Center, CA/Simon,R., University of Michigan Health System, MI/Smith,P., Long Island College Hospital, NY/Solomon,M., The Hospital for Sick Children, Toronto, Canada/Spencer,T., Children's Hospital of Boston, MA/Stecenko,A., Emory University, GA/Stokes,D., University of Tennessee, TN/Sullivan,B., Marshfield Clinic, WI/Taylor-Cousar,J., University of New Mexico, NM/Taylor,C., University of Sheffield, United Kingdom/Thomas,N., Pennsylvania State University College of Medicine, PA/Thompson,H., St. Luke's CF Clinic, ID/Toder,D., Children's Hospital of Michigan and Harper University Hospital, MI/Tullis,E., St.Michael’s Hospital, Toronto, Canada/Turcios,N., University of Medicine & Dentistry of NJ, NJ/Van Biervliet,S., Ghent University Hospital, Belgium/van Wylick,R., Hotel Dieu Hospital, Kingston, Canada/Varlotta,L., St. Christopher's Hospital for Children, PA/Vauthy,P., Toledo Children's Hospital, OH/Voynow,J., Duke University, NC/Wainwright,C., Royal Children's Hospital, Australia/Walker,P., St. Vincent’s Hospital - Manhattan, NY/Warren,W.S., Hershey Medical Center, PA/Waters,I., Royal Jubilee Hospital, Victoria, Canada/Wilmott,R., St. Louis University, MO/ Wilcox,P., St. Paul’s Hospital, Vancouver, Canada/Wilschanski,M., Hadassah Medical Organization, Israel/Wojtczak,H., Naval Medical Center - San Diego, CA/Yee,W., New England Medical Center, MA/Zacher,C., St. Alexius Heart & Lung CF Clinic, ND/Zanni,R., Monmouth Medical Center, NJ/Zeitlin,P., Johns Hopkins Hospital, MD/Zuberbuhler,P., University of Alberta Hospitals, Edmonton, Canada.

Contributing French CF Centers and Principal Investigators

Abely,M., American Memorial Hospital, Reims/Bassinet,L., Centre Hospitalier Intercommunal de Créteil, Créteil/Belleguic,C., Hôpital Pontchaillou, Rennes/Bellon,G., Hôpital Femme Mère Enfant, Bron/Bessaci,K., American Memorial Hospital, Reims/Bonnel,A.S., Hôpital André Mignot, Le Chesnay/Bremont,F., Hôpital des Enfants de Toulouse, Toulouse/Brouard,J., Centre Hospitalier Universitaire de Caen, Caen/Bui,S., Hôpital Des Enfants Groupe Pellegrin, Bordeaux/Chiron,R., Hôpital Arnaud de Villeneuve, Montpellier/Chumbi-Flores,R., Hôpital de la Tronche, Grenoble/Dalphin,J.C., CNRS-UFC, UMR 6249 Chrono-environnement, Hôpital Jean Minjoz, Besançon/Dalphin,M.L., Centre Hospitalier Universitaire de Besançon, Besançon/David,V., Hôpital Mère-Enfant, Nantes/De Miranda,S., Hôpital Foch, Suresnes/Derelle,J., Hôpital d’Enfants, Vandoeuvre les Nancy/Domblides,P., Hôpital Haut Lévêque, Pessac/Dominique,S., Centre Hospitalier Universitaire Charles Nicolle, Rouen/Dubus,J.C., Hôpital d’Enfants de la Timone, Marseille/Durieu,I., UCBL1,Groupe Hospitalier Lyon Sud - Hospices Civils de Lyon, Pierre Bénite/Dury,S., Hôpital Maison Blanche, Reims/Ellafi,M., Centre Hospitalier Universitaire de Caen, Caen/Epaud,R., Centre Hospitalier Intercommunal de Créteil, Créteil/Fanton,A., Hôpital d’Enfants du Bocage, Dijon/Fayon,M., Hôpital Des Enfants Groupe Pellegrin, Bordeaux/Fleurence,E., Hôpital d’Enfants, Saint-Denis de la Réunion/Foucaud,P., Hôpital André Mignot, Le Chesnay/Ginies,J.L., Centre Hospitalier Universitaire d’Angers, Angers/Godbert,B., Hôpital de Brabois, Vandoeuvre les Nancy/Grenet,D., Hôpital Foch, Suresnes/Guillot,M., Centre Hospitalier Robert Bisson, Lisieux/Heraud,M. C., Centre Hospitalier Estaing, Clermont-Ferrand/Housset,B., Centre Hospitalier Intercommunal de Créteil, Créteil/Hubert,D., Hôpital Cochin, Paris/Huet,F., Hôpital d’Enfants du Bocage, Dijon/Kessler,R., Hôpital Civil, Strasbourg/Labbé,A., Centre Hospitalier Estaing, Clermont-Ferrand/Laurans,M., Centre Hospitalier Universitaire de Caen, Caen/Le Bourgeois,M., Necker Hôpital d’Enfants Malades, Paris/Le Roux,P., Hôpital Jacques Monod, Montivilliers/Llerena,C., Hôpital de la Tronche, Grenoble/Loeuille,G.A., Centre Hospitalier de Dunkerque, Dunkerque/Marguet,C., Centre Hospitalier Universitaire Charles Nicolle, Rouen/Melly,L., Hôpital Renée Sabran, Giens/Moisan-Petit,V., Centre Hospitalier Bretagne Atlantique, Vannes/Munck,A., Hôpital Robert Debré, Paris/Murris-Espin,M., Hôpital Larrey, Toulouse/Nove-Josserand,R., Groupe Hospitalier Lyon Sud - Hospices Civils de Lyon, Pierre Bénite/Pautard,J.C., Hôpital Nord, Amiens/Pin,I., INSERM U823 Université Joseph Fourier,Hôpital de la Tronche, Grenoble/Pramil,S., Centre Hospitalier Universitaire Charles Nicolle, Rouen/Prevota,A., Hôpital Calmette, Lille/Rames,C., Hôpital Nord, Amiens/Rault,G., Centre de Perharidy, Roscoff/Reix,P., Hôpital Femme Mère Enfant, Bron/Remus,N., Centre Hospitalier Intercommunal de Créteil, Créteil/Renouil,M., Groupe Hospitalier Sud Réunion, Saint-Pierre de la Réunion/Reynaud-Gaubert,M., Hôpital Nord, Marseille/Richaud Thiriez,B., Hôpital Jean Minjoz, Besançon/Roussey,M., Université de Rennes 1, Hôpital Sud Annexe Pédiatrique, Rennes/Sermet-Gaudelus,I., Necker Hôpital d’Enfants Malades, Paris/Stremler,N., Hôpital d’Enfants de la Timone, Marseille/Uffredi,M.L., Centre Hospitalier Bretagne Atlantique, Vannes/Urban,T., Centre Hospitalier Universitaire d’Angers, Angers/Vigneron,P., Centre Hospitalier Bretagne Sud, Lorient/Wallaert,B., Hôpital Calmette, Lille/Weiss,L., Hôpital de Hautepierre, Strasbourg.

1. Kerem B,et al. Identification of the cystic fibrosis gene: genetic analysisScienceYear: 1989245107310802570460
2. Welsh MJ,Ramsey BW,Accurso FJ,Cutting GR,et al. Cystic fibrosis. In The Metabolic and Molecular Bases of Inherited DiseaseYear: 2001New YorkMcGraw-Hill, Inc51215188
3. Blackman SM,et al. Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosisGastroenterologyYear: 20061311030103917030173
4. Li W,et al. Understanding the population structure of North American patients with cystic fibrosisClin. GenetYear: 20117913614620681990
5. Wright FA,et al. Genome-wide association and linkage identify modifier loci of lung disease severity in cystic fibrosis at 11p13 and 20q13.2Nat. GenetYear: 20114353954621602797
6. Liang K-Y,Zeger S. Longitudinal data analysis using generalized linear modelsBiometrikaYear: 1986731322
7. Dudbridge F,Gusnanto A. Estimation of significance thresholds for genomewide association scansGenet. EpidemiolYear: 20083222723418300295
8. Li Y,Willer C,Sanna S,Abecasis G. Genotype imputationAnnu. Rev. Genomics Hum. GenetYear: 20091038740619715440
9. Li Y,Willer CJ,Ding J,Scheet P,Abecasis GR. MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypesGenet. EpidemiolYear: 20103481683421058334
10. Birney E,et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot projectNatureYear: 200744779981617571346
11. Nagelkerke NJD. A note on a general definition of the coefficient of determinationBiometrikaYear: 199178691692
12. Hodges CA,Grady BR,Mishra K,Cotton CU,Drumm ML. Cystic fibrosis growth retardation is not correlated with loss of Cftr in the intestinal epitheliumAm. J. Physiol. Gastrointest.Liver PhysiolYear: 2011301G528G53621659619
13. Carbon S,et al. AmiGO: online access to ontology and annotation dataBioinformaticsYear: 20092528828919033274
14. Ashburner M,et al. Gene ontology: tool for the unification of biology. The Gene Ontology ConsortiumNat. GenetYear: 200025252910802651
15. GO-ConsortiumThe Gene Ontology in 2010: extensions and refinementsNucleic Acids ResYear: 201038D331D33519920128
16. Sun L,Craiu RV,Paterson AD,Bull SB. Stratified false discovery control for large-scale hypothesis testing with application to genome-wide association studiesGenet.EpidemiolYear: 20063051953016800000
17. Yoo YJ,Bull SB,Paterson AD,Waggott D,Sun L. Were genome-wide linkage studies a waste of time? Exploiting candidate regions within genome-wide association studiesGenet. EpidemiolYear: 20103410711819626703
18. Tibshirani R. Regression shrinkage and selection via the lassoJournal of the Royal Statistical Society. Series BYear: 199658267288
19. Purcell SM,et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorderNatureYear: 200946074875219571811
20. Pedroso I,Breen G. Gene set analysis and network analysis for genome-wide association studies' in Genetics of Complex Human Diseases - A Laboratory ManualYear: 2009New YorkCold Spring Harbor Laboratory Press
21. Wang K,Li M,Bucan M. Pathway-Based Approaches for Analysis of Genomewide Association StudiesAm. J. Hum. GenetYear: 2007811278128317966091
22. Cantor R,Lange K,Sinsheimer J. Prioritizing GWAS results: A review of statistical methods and recommendations for their applicationAm. J. Hum. GenetYear: 20108662220074509
23. Yu K,et al. Pathway analysis by adaptive combination of P-valuesGenet. EpidemiolYear: 20093370070919333968
24. Thomas DC,et al. Use of pathway information in molecular epidemiologyHum. GenomicsYear: 20094214221072972
25. Bradford EM,Sartor MA,Gawenis LR,Clarke LL,Shull GE. Reduced NHE3-mediated Na+ absorption increases survival and decreases the incidence of intestinal obstructions in cystic fibrosis miceAm. J. Physiol. Gastrointest. Liver Physiol.yYear: 2009296G886G898
26. Fraga S,Serrao MP,Soares-da-Silva P. L-type amino acid transporters in two intestinal epithelial cell lines function as exchangers with neutral amino acidsJ. NutrYear: 200213273373811925469
27. Höglund PJ,Adzic D,Scicluna SJ,Lindblom J,Fredriksson R. The repertoire of solute carriers of family 6: Identification of new human and rodent genesBiochem. Biophys. Res. CommunYear: 200533617518916125675
28. Chang MH,et al. Slc26a9--anion exchanger, channel and Na+ transporterJ. Membr. BiolYear: 200922812514019365592
29. Chang MH,et al. Slc26a9 is inhibited by the R-region of the cystic fibrosis transmembrane conductance regulator via the STAS domainJ. Biol. ChemYear: 2009284283062831819643730
30. Bertrand CA,Zhang R,Pilewski JM,Frizzell RA. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epitheliaJ. Gen. PhysiolYear: 200913342143819289574
31. Dorfman R,et al. Modulatory effect of the SLC9A3 gene on susceptibility to infections and pulmonary function in children with cystic fibrosisPediatr. PulmonolYear: 20114638539220967843
32. Pedemonte N,et al. Small-molecule correctors of defective ΔF508-CFTR cellular processing identified by high-throughput screeningJ. Clin. InvestYear: 20051152564257116127463
33. The ENCODE Project ConsortiumA User's Guide to the Encyclopedia of DNA Elements (ENCODE)PLoS BiolYear: 20119 e1001046.
34. Wood SD,et al. Inaccuracy of reporting of meconium ileus on case report forms of the gene modifier study. Abstract #200Pediatr. Pulmonol. SupplYear: 200742272
35. Price AL,Patterson NJ,Plenge RM,Weinblatt ME,Shadick NA,Reich D. Principal components analysis corrects for stratification in genome-wide association studiesNat. GenetYear: 20063890490916862161
36. Purcell S,et al. PLINK: a tool set for whole-genome association and population-based linkage analysisAm. J. Hum. GenetYear: 20078155957517701901
37. Dmitromanolakis A,Paterson AD,Sun L. Accurate IBD inference identifies cryptic relatedness in 9 HapMap populationsYear: 2009American Society of Human Genetics - 59th Annual Meeting Abstract #1768.
38. Durbin RM,et al. A map of human genome variation from population-scale sequencingNatureYear: 20104671061107320981092
39. Roeder K,Bacanu S,Wasserman L,Devlin B. Using Linkage Genome Scans to Improve Power of Association in GenomeScansAm. J. Hum. GenetYear: 20067824325216400608

Article Categories:
  • Article

Previous Document:  Mutations in UVSSA cause UV-sensitive syndrome and destabilize ERCC6 in transcription-coupled DNA r...
Next Document:  Clinical observation of immunity in patients with secondary infection from severe acute pancreatitis...